Otofarma (OTO) H2 2025 earnings summary

Executive summary

• FY25 preliminary pro forma revenue reached €16.5m, up 10% YoY; adjusted EBITDA was €2.4m, with profitability described as stable.

• H2 2025 actions focused on protecting margins; management expects these measures to continue benefiting results in 2026.

Financial highlights

• FY25 revenue grew 10% YoY to €16.5m, with moderate growth in H2.

• Adjusted EBITDA totaled €2.4m; cost rationalization, efficiency measures and a stronger product mix supported results.

Outlook and guidance

• Margin-protection measures are expected to continue supporting performance in 2026, alongside new AI-based devices and the gradual rollout of the Convergence Plan – Otofarma 2.0.

• AI-based devices launched in January 2026.